Umlaut.bio
Umlaut.bio35
About
What does Umlaut.bio do?
Umlaut.bio is a biotechnology company focused on developing novel immunotherapies for cancer. They leverage their proprietary platform to discover and develop new therapeutic candidates. The company has recently secured significant pre-seed funding to advance its research and development efforts.
What is Umlaut.bio's revenue?
StartupHub estimates Umlaut.bio's annual revenue at $232K (range $76K to $784K, 33% confidence), based on comparable companies in the sector.
What is Umlaut.bio's valuation?
StartupHub estimates Umlaut.bio's effective valuation at $11.1M (range $7.5M to $18.0M, 22% confidence), based on comparable companies in the sector.
How much funding has Umlaut.bio raised?
Umlaut.bio has raised a total of $3M in funding. The most recent round on record is Pre-Seed.
Where is Umlaut.bio headquartered?
Umlaut.bio is headquartered in Cambridge, Massachusetts, USA.
When was Umlaut.bio founded?
Umlaut.bio was founded in 2022.
What industry does Umlaut.bio operate in?
Umlaut.bio operates in Biotechnology, Cancer, Immunotherapy, Drug Discovery.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.